Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

Does CRISPR-Cas open new possibilities for patents or present a moral maze?

Nature Biotechnology volume 32, pages 331–333 (2014)Cite this article

Subjects

CRISPR-Cas systems, which enable the production of new artificial genes, synthetic proteins and new transgenic organisms, will challenge patent practices worldwide.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jinek, M. et al. Science 337, 816–821 (2012).

    Article  CAS  Google Scholar 

  2. Jiang, W. et al. Nat. Biotechnol. 31, 233–239 (2013).

    Article  CAS  Google Scholar 

  3. Cho, S.W. et al. Nat. Biotechnol. 31, 230–232 (2013).

    Article  CAS  Google Scholar 

  4. Hwang, W.Y. et al. Nat. Biotechnol. 31, 227–229 (2013).

    Article  CAS  Google Scholar 

  5. Urnov, F.D. et al. Nat. Rev. Genet. 11, 636–646 (2010).

    Article  CAS  Google Scholar 

  6. Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al. http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf (13 June 2013).

  7. Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions, Official Journal L213, 0013–0021 (30 July 1998). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31998L0044:EN:HTML

  8. Diamond v. Chakrabarty, 447 US 303 (1980).

  9. Patent no. 3, granted in Finland in 1843.

  10. Plant Genetics Systems NV and Biogen, Inc. European Patent No. 0 242 236 (10 October 1990).

  11. T0356/93 Plant cells/Plant Genetic Systems http://www.epo.org/law-practice/case-law-appeals/recent/t930356ep1.html

  12. T 0019/90 Onco-Mouse/Harvard http://www.epo.org/law-practice/case-law-appeals/recent/t900019ex1.html.

  13. Recital 16 of the Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions, Official Journal L213, 0013–0021 (30 July 1998). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31998L0044:EN:HTML

Download references

Author information

Authors and Affiliations

  1. Philip Webber is at Dehns Patent and Trade Mark Attorneys, Oxford, UK.,

    Philip Webber

Authors
  1. Philip Webber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip Webber.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Webber, P. Does CRISPR-Cas open new possibilities for patents or present a moral maze?. Nat Biotechnol 32, 331–333 (2014). https://doi.org/10.1038/nbt.2843

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2843

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing